Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study

This phase 2 observer-blind, randomized, multicenter, dose-ranging study evaluated immunogenicity and safety of different formulations of an AS03-adjuvanted H5N1 influenza vaccine in children 6–35 months of age. METHODS: One hundred eighty-five children randomized into 5 groups [1.9 µg hemagglutinin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joon Hyung, Drame, Mamadou, Puthanakit, Thanyawee, Chiu, Nan-Chang, Supparatpinyo, Khuanchai, Huang, Li-Min, Chiu, Cheng-Hsun, Chen, Po-Yen, Hwang, Kao-Pin, Danier, Jasur, Friel, Damien, Salaun, Bruno, Woo, Wayne, Vaughn, David W., Innis, Bruce, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Vaccine Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357047/
https://www.ncbi.nlm.nih.gov/pubmed/34285165
http://dx.doi.org/10.1097/INF.0000000000003247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357047/
https://www.ncbi.nlm.nih.gov/pubmed/34285165
http://dx.doi.org/10.1097/INF.0000000000003247

Ejemplares similares